The Dawn of a New Era of Therapies in Systemic Lupus Erythematosus.
The Dawn of a New Era of Therapies in Systemic Lupus Erythematosus.
复制标题
DOI：
10.2478/rir-2020-0005
复制
发表时间：
2020-12
期刊：
影响因子：
--
通讯作者：
Mok, Chi Chiu
中科院分区：
文献类型：
--
作者：
Mok, Chi Chiu
系统性红斑狼疮 (SLE) 是一种复杂的多系统自身免疫性疾病，与年轻人群的显着死亡率和发病率相关。由于其临床和免疫学异质性、多系统结果评估的复杂性以及优化临床试验设计的困难，SLE新疗法的开发落后于其他自身免疫性炎症性风湿病。尽管相当多的临床试验都是徒劳的，但考虑到新一代抗 CD20、抗 CD40L 生物制剂和钙调神经磷酸酶抑制剂 (CNI) 以及抗细胞因子生物制剂、Jakinibs 和哺乳动物雷帕霉素靶点 (mTOR) 抑制剂的良好结果，我们看到了治疗 SLE 的新疗法的曙光。 Jakinib 和联合治疗方案在 SLE 中的初步成功说明了针对多种发病机制的重要性。正在进行的 SLE III 期临床试验的结果备受期待。
Systemic lupus erythematosus (SLE) is a complicated multisystem autoimmune disease that is associated with significant mortality and morbidity in the younger population. The development of novel therapies of SLE lag behinds other autoimmune inflammatory rheumatic diseases because of its clinical and immunological heterogeneities, the complexity of outcome assessments in multiple systems, and difficulty in optimizing the design of clinical trials. Despite the futility of quite a number of clinical trials, we are seeing the dawn of novel therapeutics in SLE, given the promising results of the newer-generation anti-CD20, anti-CD40L biologics, and calcineurin inhibitors (CNIs), as well as anti-cytokine biologics, Jakinibs, and the mammalian target of rapamycin (mTOR) inhibitors. The initial success of the Jakinibs and combination regimens in SLE illustrates the importance of targeting multiple pathogenetic mechanisms. The results of the ongoing phase III clinical trials in SLE are eagerly awaited.
登录
查看更多内容
DOI：
10.1002/art.39856
发表时间：
2017-02
期刊：
Arthritis & rheumatology (Hoboken, N.J.)
影响因子：
--
作者：
Clowse ME;Wallace DJ;Furie RA;Petri MA;Pike MC;Leszczyński P;Neuwelt CM;Hobbs K;Keiserman M;Duca L;Kalunian KC;Galateanu C;Bongardt S;Stach C;Beaudot C;Kilgallen B;Gordon C;EMBODY Investigator Group
通讯作者：
EMBODY Investigator Group
影响因子：
27.4
作者：
Houssiau, Frederic A.;Thanou, Aikaterini;Lucas Tee, Michael
通讯作者：
Lucas Tee, Michael
影响因子：
12.8
作者：
Kraaij, Tineke;Kamerling, Sylvia W. A.;Teng, Y. K. Onno
通讯作者：
Teng, Y. K. Onno
影响因子：
4.9
作者：
Ginzler EM;Wax S;Rajeswaran A;Copt S;Hillson J;Ramos E;Singer NG
通讯作者：
Singer NG
影响因子：
27.4
作者：
Khamashta M;Merrill JT;Werth VP;Furie R;Kalunian K;Illei GG;Drappa J;Wang L;Greth W;CD1067 study investigators
通讯作者：
CD1067 study investigators